Colin Bristow Analyst PerformanceAnalyst at UBS GroupColin Bristow is a stock analyst at UBS Group in the medical sector, covering 13 publicly traded companies. Over the past year, Colin Bristow has issued 10 stock ratings, including buy and hold recommendations. While full access to Colin Bristow's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Colin Bristow's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings34 Last 10 YearsBuy Recommendations62.96% 17 Buy RatingsCompanies Covered13 Unique Companies Ratings Distribution27RatingsDistribution of strong buy, buy, hold, and sell ratings by Colin Bristow.RatingPercentageCount Strong Buy0.0%0 ratings Buy63.0%17 ratings Hold37.0%10 ratings Sell0.0%0 ratingsOut of 27 total stock ratings issued by Colin Bristow at UBS Group, the majority (63.0%) have been Buy recommendations, followed by 37.0% Hold.Best & Worst CallsBest Call000.0%PFENov 2016Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%LLYDec 2015Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ69.2% of companies on NASDAQ9 companiesNYSE30.8% of companies on NYSE4 companiesColin Bristow, an analyst at UBS Group, currently covers 13 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical13 companies100.0%Colin Bristow of UBS Group specializes in stock coverage within the Medical sector.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE9 companies69.2%LARGE CAP PHARMA4 companies30.8% Colin Bristow's Ratings History at UBS Group Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export to Excel CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsGILDGilead Sciences8/8/2025Boost Price Target$120.14$112.00Neutral$0.0000.00% ROIVRTXVertex Pharmaceuticals8/5/2025Set Price Target$401.07$553.00Buy$0.0000.00% ROIPTCTPTC Therapeutics7/29/2025Boost Price Target$48.86$80.00Buy$0.0000.00% ROIRCKTRocket Pharmaceuticals6/17/2025Lower Price Target$2.91$5.00Buy$0.0000.00% ROIALXOALX Oncology5/21/2025Lower Price Target$0.44$1.00Buy$0.0000.00% ROIIMVTImmunovant4/22/2025Reiterated Rating$14.46$17.00Neutral$0.0000.00% ROIAMGNAmgen4/14/2025Boost Price Target$293.92$319.00Neutral$0.0000.00% ROIABOSAcumen Pharmaceuticals3/28/2025Lower Price Target$1.18$4.00Buy$0.0000.00% ROIENGNenGene2/14/2025Downgrade$6.25$7.00Neutral$0.0000.00% ROIALXOALX Oncology1/27/2025Lower Price Target$1.47$2.20Buy$0.0000.00% ROI Stock Forecasts and Research Tools Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
